Moin Saleem

Moin Saleem is a co-founder and CSO of Purespring Therapeutics.

Moin is also Professor of Paediatric Renal Medicine at the University of Bristol and Director of Bristol Renal, a glomerular research group of approximately 45 researchers, covering all areas from cell biology, transgenic models and population cohorts and genetics.

Moin is the originator of the gold-standard human podocyte cell ines, used worldwide for academic and industry research. Moin also set up the UK Renal Rare Disease Registry (RaDaR), and is currently leading the UK nephrotic syndrome study (NephroS), as well as a major industry-academic collaboration termed NURTuRE (National Unified Renal Translational Research Enterprise).

His gene therapy programme commenced in 2014, and is focused on targeting the podocyte in order to radically change the treatment of kidney diseases. Moin trained as an undergraduate at University College, London, and is a Fellow of the Royal College of Physicians. His PhD was in transplantation immunology at the Institute of Child Health, London, followed by Paediatric Nephrology training at Great Ormond Street Hospital, London.